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ABSTRACT Saccharomyces cerevisiae strains expressing
the activated RAS2vaI19 gene or lacking both cAMP phospho-
diesterase genes, PDEI and PDE2, have impaired growth
control and display an acute sensitivity to heat shock. We have
isolated two classes of mammalian cDNAs from yeast expres-
sion libraries that suppress the heat shock-sensitive phenotype
of a RAS2vaI9 strain. Members of the first class of cDNAs also
suppress the heat shock-sensitive phenotype of pdel- pde2-
strains and encode cAMP phosphodiesterases. Members of the
second class fail to suppress the phenotype of pdel- pde2-
strains and therefore are candidate cDNAs encoding proteins
that interact with RAS proteins. We report the nucleotide
sequence of three members of this class. Two of these cDNAs
share considerable sequence similarity, but none are clearly
similar to previously isolated genes.
The mammalian RAS genes were first discovered as ho-
mologs of retroviral oncogenes (1). Activated, mutant RAS
alleles are frequently found in human tumors (2). RAS
homologs have been found and described in many eukaryotic
organisms (3-7). In the yeast Saccharomyces cerevisiae
products ofthe twoRAS homologs, RAS] and RAS2, activate
adenylyl cyclase (8, 9). Although mammalian RAS proteins
can function in this way when expressed in yeast (10, 11), the
function of mammalian RAS in mammalian cells is still
unknown. One candidate target of mammalian RAS action is
GAP, the GTPase-activating protein, which also has been
proposed as a regulator of RAS action (12, 13).
Like mammalian RAS, the yeast RAS2 gene can be acti-
vated by point mutation (14). Yeast containing RAS2v`l9
have multiple defects. They are sensitive to heat shock and
cannot survive prolonged nutrient deprivation (8, 15). The
same phenotypes are also seen in pdel- pde2- yeast, which
lack cAMP phosphodiesterases (16). The aberrant pheno-
types of both RAS2va1l9 and pdel- pde2- strains can be
suppressed by overexpression of yeast or mammalian phos-
phodiesterases (16, 17). Expression of enzymatically inactive
adenylyl cyclase, the target of RAS action in yeast, can also
suppress the phenotype of RAS2v`l9 strains but cannot
suppress the phenotype of pdel- pde2- strains (18). The
ability of truncated adenylyl cyclase to interfere with RAS
function probably reflects its nonproductive interactions with
RAS.
We have screened libraries of mammalian cDNAs, cloned
into yeast expression vectors, for those cDNAs capable of
suppressing the phenotype ofRAS2vaIl9 yeast. We previously
reported isolating in this manner a rat gene encoding a cAMP
phosphodiesterase homologous to the Drosophila melano-
gaster dunce protein (17). The rat cDNA also suppresses the
phenotype of pdel- pde2- yeast and presumably works by
lowering intracellular cAMP concentrations. We now report
three new human cDNAs§ that suppress the phenotypes of
RAS2vaIl9 yeast but fail to suppress the phenotypes ofpdel -
pde2- yeast. These cDNAs therefore may encode mamma-
lian proteins that interact directly with RAS proteins.
MATERIALS AND METHODS
Strains, Growth Conditions, Heat Shock Assays, and Seg-
regation Analysis. Plasmids were propagated in Escherichia
coli strains HB101 or SCS1 (Stratagene). S. cerevisiae strains
TK161RV (MATa RAS2vail9 Ieu2 his3 ura3 ade8 trpl) (8) and
10DAB (MATa leu2 his3 ura3 ade8pdel: :ADE8pde2:: URA3
rasl::HIS3) (17) were grown in rich medium [yeast extract/
peptone/dextrose (YPD)] or synthetic medium (SC) with
appropriate supplements. Heat shock assays were performed
as described (17). Yeast transformants were plated at 4103
colonies per plate on selective medium. Colonies were al-
lowed to grow for 3 days and then were replica-plated onto
preheated plates. Heat shocks were carried out at 550C for 10
min and followed by 2-3 days of recovery at 30'C. Surviving
colonies were picked, restreaked on synthetic medium plates
for colony purification, and then cultured in rich medium for
2-3 days to allow for plasmid loss from some cells. Of these
cultures, 1 ,.d was plated onto YPD plates. After 2-3 days of
growth, colonies were replica-plated onto synthetic medium
plates (Leu+ selection), YPD plates, and YPD heat shock
plates. Colonies were scored to ascertain ifthe observed heat
shock resistance was plasmid dependent.
Vector Construction and Cloning. The expression vector
pADNS has been described (17). pADNS contains the alco-
hol dehydrogenase gene ADHI promoter immediately fol-
lowed by unique HindIII and Not I cloning sites. pADANS
was constructed as follows. A polymerase chain reaction
(PCR) was carried out on the yeast ADHI gene in pJD14 (19).
The first oligonucleotide primer (5'-TCTAAACCGTG-
GAATATT) was placed within the promoter region of the
gene and upstream of theEcoRV site within the promoter that
is also contained in pADNS. The second primer (5'-
GTCAAAGCTTCGTAGAAGATAACACC) is complemen-
tary to the coding stand of the ADHI gene. This primer
included additional sequences that incorporate a new HindIII
endonuclease recognition site. The PCR product was then
purified, digested with EcoRV and HindIII, and ligated
together with the 8.0-kilobase (kb) EcoRV/HindIII-digested
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FIG. 1. The heat shock-sensitive strains TK161-R2V (RAS2vll9)
and 10DAB (pdel- pde2-) were transformed with the cloning vector
pADANS or with plasmids expressing each of the cDNA isolates.
Transformants were patched in duplicate on synthetic medium plates
and replica-plated onto fresh plates without heat shock (Left) or with
heat shock (Right). All plates were then incubated at 30°C for 48 hr.
Longer duration of the heat shock (20 min) indicated that JC310 is a
weaker suppressor than the others (data not shown).
fragment of pADNS. (Since the EcoRV site is not unique in
pADNS, the 8.0-kb fragment was obtained by partial diges-
tion.) The resulting plasmid, pADANS, thus contains the
entire ADHJ promoter and the first 14 amino acid codons of
the ADH1 gene followed by the HindIII and Not I restriction
endonuclease sites.
cDNA was prepared from poly(A)+ mRNA isolated from
the human glioblastoma cell line U118-MG (Human Tumor
Cell Line Bank, Human Tumor Cell Laboratory, Memorial
Sloan-Kettering Cancer Institute) (20) by standard proce-
dures (21). cDNAs were ligated to Not I linkers as described
(17) and cloned into A ZAP (Stratagene). Approximately 1.5
x 106 recombinant phage were obtained, and the average
insert size was 1.5 kilobase pairs (kbp). The phage library
DNA (10 mg) was digested with Not I, and insert fragments
were purified and size-selected on a 10-40% sucrose gradient
JC99
(22). Insert DNA fragments were then ligated with Not
I-cleaved, phosphatase-treated pADANS. SCS1 cells were
used as transformation recipients. One-liter cultures were
prepared for transformation by standard procedures (23).
Transformation efficiency was monitored by plating a small
portion ofthese cells onto ampicillin plates. The remainder of
the culture was selected for ampicillin-resistant transfor-
mants in liquid culture, and plasmid DNA was prepared by
CsCl gradient purification (24). The library DNA thus ob-
tained was used to transform TKRV-161 yeast cells by the
lithium acetate method (25).
DNA Sequence Analysis. DNA sequencing was performed
by the dideoxynucleotide chain-termination method (26, 27).
GENALIGN was used for pairwise amino acid sequence align-
ments (GENALIGN is a copyrighted software product of In-
telliGenetics, developed by Hugo Martinez). Pairwise ho-
mology search programs used were FASTA 28 and FASTDB
(IntelliGenetics). GenBank, European Molecular Biology
Laboratory, Swiss-Prot, and PIR (Protein Information Re-
source) data bases were searched. We used the MACAW
program for multiple sequences-alignment searches (29).
RESULTS AND DISCUSSION
Isolation and Genetic Characterization of cDNA Suppres-
sors. In our previous work we utilized the yeast expression
vector pADNS (17). This vector supplied a strong yeast
transcriptional promoter, the ADHI promoter, and ADHI
transcription termination sequences. Initiation codons were
provided by cDNA inserts. We have used a modified vector,
pADANS, to express cDNA inserts as fusion proteins con-
taining the first 14 amino acids of the ADH1 protein. For
expression in pADANS, cDNA inserts do not need an
in-frame methionine codon. In addition, all expressed gene




























FIG. 2. The cDNA sequence and predicted amino acid sequence of JC99 are presented. Translation initiation is at the ADHI methionine
codon located 54 nucleotides upstream of the sequence presented. The amino acids encoded by the ADHI sequence and the adjacent HindIll
and Not I sites of the polylinker are: Met-Ser-Ile-Pro-Glu-Thr-Gln-Lys-Gly-Val-Ile-Phe-Tyr-Glu-Ala-Cys-Gly-Arg. Nucleotide and amino acid
coordinates are given in the right margin. Numbering begins with the cDNA sequence and does not include the fusion sequences described above.
The calculated molecular mass of the predicted polypeptide shown is 45 kDa.
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derived from an endogenous, stable, cytoplasmically ex-
pressed yeast protein. In our previous work we utilized
cDNAs obtained from poly(A)+ rat brain mRNA. In this
work, we synthesized cDNAs from poly(A)+ mRNA pre-
pared from the human glioblastoma cell line U118-MG. These
cDNAs were first cloned as Not I fragments into A ZAP and
subsequently transferred into pADANS. A library of com-
plexity 1.5 x 106 was obtained.
The RAS2v'aI9 yeast strain, TK-161R2V, was transformed
with library DNA, and 5 x 105 transformants were screened
for sensitivity to heat shock by a replica plate method.
Twenty-eight colonies were found that contained plasmid
DNAs capable of suppressing the heat shock-sensitive phe-
notype ofTK-161R2V. These plasmids contained four groups
of related cDNAs. The largest group, with 22 members, is
represented by cDNA JC99. The next largest, with 4 mem-
bers, is represented by cDNA JC44. JC265 and JC310 were
found once each.
Plasmids containing representative cDNAs were tested for
their effects on the pdel- pde2- strain, lODAB (see Fig. 1).
Although all plasmids could suppress the heat shock-
sensitive phenotype of TK-161R2V, only the plasmid con-
taining JC44 could suppress the heat shock phenotype of
lODAB. The amino-terminal amino acid sequences derived
from the expression vector (see the legend of Fig. 2) are not
required for this assay, since when these sequences were
replaced with a different amino-terminal epitope fusion (9),
the same results were obtained (data not shown).
Sequence ofcDNA Suppressors. The cDNAs corresponding
to JC44, JC99, JC265, and JC310 were sequenced. JC44, the
cDNA capable of suppressing pdel-pde2- yeast, is a human
homolog of the rat dunce protein-like phosphodiesterase,
which we isolated in a previous screen. Its sequence appears
to be identical to a recently reported human phosphodi-
JC265
esterase gene (30) and is not reported here. The entire
nucleotide sequences of the other cDNAs are shown in Figs.
2, 3, and 4. JC99 contains an open reading frame of420 amino
acids. JC265 has an open reading frame of 471 amino acids.
JC310 has an open reading frame of429 amino acids. All open
reading frames are in-frame with the leader peptides of the
expression vector. The open reading frames of JC99 and
JC265 terminate with stop codons. The open reading frame of
JC310 continues into the vector.
We searched existing data banks for nucleotide or amino
acid sequences similar to JC99, JC265, and JC310. No
striking similarities were found to other genes in the pairwise
searches of sequence data bases. However, JC99 and JC265
share extensive amino acid sequence similarity with each
other (see Fig. 5A). Overall there is 38% sequence identity
between the products of these two genes. In one stretch of47
amino acids, there is 70%6 identity and about 80%6 similarity
when one includes conservative amino acid changes. Neither
gene shows significant similarity to JC310.
Despite the failure of computer searches to uncover sim-
ilarities to the predicted protein products ofJC99, JC265, and
JC310 cDNAs in pairwise searches of large data bases, we
performed multiple sequence alignment searches with amino
acid sequences of proteins known or thought to interact with
RAS. These sequences included human GAP (32), the yeast
IRA1 and IRA2 proteins (33, 34), which are functionally
homologous to GAP (35), NF1 (36, 37), which is the protein
encoded by the von Recklinghausen neurofibromatosis locus
that is related to both GAP and the IRA proteins (inhibitory
regulators of the RAS-cAMP pathway) (38-40), and sarl,
which is a protein in Schizosaccharomyces pombe that is
also related to GAP, NF1, and the IRA proteins (Y. Wang
and M.W., unpublished data). Marginal similarities were





























FIG. 3. The cDNA sequence and predicted amino acid sequence of JC265 are presented. The calculated molecular mass of the predicted
polypeptide shown is 54 kDa. See also comments in the legend to Fig. 2.
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FIG. 4. The cDNA seaquence and predicted amino acid sequence of JC310 are presented.. The calculated molecular mass of the predicted
polypeptide shown is 48 kDa. No stop codon was found in the correct reading frame. See also comments in'the legend to Fig. 2.
quences. The only similarity between all of the sequences Functiokal Sig zace. We have isolated several mamma-
occurred within the region common to all GAP-like mole- liangenesthatinterferewiththefunctionoftheRASpathway
cules. Thi's alignment is presented in Fig. 5B. Similar in the yeast S. cerevisiae. Three of these genes do not
searches were conducted with the sequences of CDC25 (41) suppress the phenotypes of yeast cells lacking phosphodi-
and SCD25(42), proteinsfrom S. cerevisiaethatarebelieved estera'ses, and since RAS simulates adenylyl cyclase, we
to activate RAS by accelerating nucleotide exchange, and infer that these three genes encode proteins that interfere
ste6 (43), a related protein from Sch. pombe. The most with the function of yeast RAS itself. In each case we appear
significantcommonalignmentwas toJC310 inaregionofthe to have isolated truncated cDNAs. We have previously
CDC25-like molecules thought to be essential for function demonstratedthatexpressionofatruncatedformofadenylyl
(44). Thi's alignment is show^n in Fig. SC. No significant cyclase, normally a RAS effector in yeast, can result in a
similarities with yeast adenylyl cyclase or RAS proteins potent disruption of RAS function (22). Nevertheless, we
themselves were found. cannot infer from our experiments the true functions of these
A
JC9 9 IGYRVPAGSGPSLPPMPSLQEVDCGS PSSSEEEGVPGSRGSPATSPHLGRRRPLLRSMSAAFCSLLAPERQVGRAAAA -MQDRHTAAGQLVQD--- -- ------LLTQVRDGQRP 104
JC265 EFDRSM4PLFGYEADTNSSLEDYBGESDQETMAPPIKSKKKRSSSFVLPKLVKSQIQV-(VFSSFMTPEKRVRIAELSRDKCTYFGCLVQDYVSFLQENKCECHVSSTDMLQ 131
JC9 9 QELEGIRQALSRARAM{LSAELGPEKLVSPKRLEHVLEKSLHCSVLKPLRPILAARLRRRLAADGSLGRtLGLRLARAQGPGAFGSHLSLPSPVELEQVRQKLLQLVRTYSPS 217
JC2 65 TIRQFMTQ~VKNYLSQSSELDPP IESLIPEDQIDVVLEKAMHKCILKPLKGHVEAXLKDFHMADGSWKQLKENLQLVRQRNPQELGVFAPTPDFVDVEKIKVKFMTQKMYSPE 24 4
JC99 AQVKRLLQACKLLYMALRTQEGEGSGAEDGFLPLLSLVLAHCDLPELLLEAEYMSELLEPSLLTGEGGYYLTSLSASLALLSGLGQAHTLPL----SPVQELRRSLSLWEQRRL 326
JC2 65 KKVMLLLRVCKLIYTVMENNSGRMYGADDFLPVLTYIAQCDMLELDrEIEYMMELLDPSLLHGEGGYYLTSAYGALSLIKNFQEEQAARLLSSETRDTlLRQWHKRRTTNRTI 35 7
JC9 9 PATHCFQHLLRVAYQDPSSGCTSRTLAVPPEASIATLNQLCATKFRVTQPNTFGLFLYKEQGYHRLPPGPWPTGCPPLATSSTAGQSGLRPRGL 42 0
JC2 65 PSVDDFQNYLRVAFQEVNSGCTGKTLLVRPY ITTEDVCQICAEKFKVGDPEEYSLFLFVDEIWQQLAEDTYPQKIKAELHSRPQPH IFHFVYKR 4 51
B C
IRA1 E Y A Y I A V G S F V F L R F G P A L V S P D|SE IVi (1724) JC310: S N A (334)
IRA2 D H A I I A A G S F V F L R F F C P A L V S P XS EN I I DIS (1870) CDC25: S A L Y S S L 7bT (1421)
NF1 QES I G A V G S EM F L R F IN P A I V S P YE A GI L D X R (1074) SCD25: S A L Y S S P I Y R L E K T W QA VIp (399)
SARl S T I C S L I GFG_ FF F L R F. V N P A I I S P Q T SM L L D S C (358) STE6: SA L NS S P F!R (138)
HGAP T M R T R V V S G F V F L R I C P AI 1k F N I I DSD (921)
JC99 T QE G EFG S G A D G_ F LP L L S L V L AHCDL P EL LrLE A (271)
JC265 N S G R M Y GA D D FLP VILIT Y V I A Q C DM L E SDT EI (296)
FIG. 5. Sequence alignments of predicted amino acid sequences. (A) The alignment of JC99 and JC265. In each pair of lines, the upper line
shows the complete sequence of JC99, and the lower line shows the sequence of JC265 beginning at amino acid residue 18 and ending at residue
451. The area ofgreatest sequence identity lies within residues 243-289 of JC99. Identities are marked with vertical lines, and conservative amino
acid differences are marked with dots. (B) The alignment of JC99 and JC265 with GTPase-activating protein (GAP)-like molecules. The
coordinates of the sequences are shown at the right margin. Regions of similarity are boxed. (C) The alignment of JC310 with CDC25-like
molecules. Coordinates are at the right, and similar residues are boxed. In A, B, and C, the grouping of similar amino acids follows the system
of Jiminez-Montano and Zamora-Cortina (31). Groupings of similar amino acids are: (V, L, I, M), (F, Y, W), (K, R), (E, D), (Q, N), (S, T),
and (A, G).
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proteins in mammalian cells. One possibility is that these
proteins interact with yeast RAS proteins fortuitously. A
second possibility is that the genes encode physiological
inhibitors of mammalian RAS-like proteins. A third possibil-
ity is that the proteins are components of mammalian RAS
targets that can compete for interaction with RAS in yeast.
Many additional experiments are required to resolve these
possibilities. In any event, we have demonstrated that genetic
screening ofcDNAs in yeast may prove to be a powerful tool
for the isolation of novel components of mammalian signal
transduction pathways.
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